Device maker HCmed Innovations has partnered with Formosa Laboratories and Formosa Pharmaceuticals to offer contract development and manufacturing services for inhaled drugs, HCmed announced. Formosa Laboratories already offers CDMO services for pharmaceutical products; the new services will also incorporate Formosa Pharmaceutical’s nanotechnology platform and HCmed’s vibrating mesh nebulizer technology.
All three companies are headquartered in Taiwan, and in 2019, HCmed announced that it was building R&D and manufacturing facilities in Wuxi, China. The company makes three handheld vibrating mesh nebulizers: Deepro, Pulmogine, and AdheResp. In August 2021, HCmed announced that it was working with Cellics Therapeutics on development of inhaled cellular nanosponges as antibacterial and anti-inflammatory therapies.
HCmed CEO Jason Cheng commented, “Currently, global CDMO companies that focus on developing drug-device combination products cannot only provide their Pharma partners with a platform to deliver drugs, but also with integrated services that extend to drug development, mass production, and product packaging. Through these services, the combination product development time can be shortened, and costs can be reduced. With this objective, HCmed, Formosa Laboratories, and Formosa Pharmaceuticals aim to provide a fully integrated CDMO service platform, which is expected to further expand the companies’ business, providing fully-integrated solutions and creating long-term win-win relationships.”
Read the HC Med press release.
